| Literature DB >> 17919329 |
Surendra P Singh1, Dinesh Arya, Trish Peters.
Abstract
BACKGROUND: Studies on the feasibility of telepsychiatry tend to concentrate only on a subset of clinical parameters. In contrast, this study utilises data from a comprehensive assessment. The main objective of this study is to compare the accuracy of findings from telepsychiatry with those from face to face interviews.Entities:
Mesh:
Year: 2007 PMID: 17919329 PMCID: PMC2194760 DOI: 10.1186/1471-244X-7-55
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Figure 1The sample randomisation. The numbers in the boxes are the serial numbers of the sample cases. Those crossed are drop-outs.
Comparison of results of telepsychiatric assessments and face-to-face interviews
| 01 | DSM-IV Axis 1 | 49 | 5 | 54 | 0.91 | 0.83 | 0.99 | 0.025 | -0.09 | -0.17 | -0.02 | 0.019 |
| 02 | DSM-IV Axis 2 | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 03 | DSM-IV Axis 3 | 36 | 2 | 38 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.12 | 0.02 | 0.146 |
| 04 | DSM-IV Axis 4 Q1 | 31 | 6 | 37 | 0.84 | 0.73 | 0.97 | 0.014 | -0.16 | -0.28 | -0.04 | 0.007 |
| 05 | DSM-IV Axis 4 Q2 | 31 | 6 | 37 | 0.84 | 0.73 | 0.97 | 0.014 | -0.16 | -0.28 | -0.04 | 0.007 |
| 06 | DSM-IV Axis 4 Q3 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 07 | DSM-IV Axis 4 Q4 | 36 | 1 | 37 | 0.97 | 0.92 | 1.03 | 0.317 | -0.03 | -0.08 | 0.03 | 0.311 |
| 08 | DSM-IV Axis 4 Q5 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 09 | DSM-IV Axis 4 Q6 | 32 | 5 | 37 | 0.86 | 0.76 | 0.98 | 0.025 | -0.14 | -0.25 | -0.02 | 0.016 |
| 10 | DSM-IV Axis 4 Q7 | 37 | 0 | 37 | 1.00 | 1.00 | 1.00 | NA | 0.00 | 0.00 | 0.00 | NA |
| 11 | DSM-IV Axis 4 Q8 | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 12 | DSM-IV Axis 4 Q9 | 1 | 36 | 37 | 0.03 | 0.00 | 0.19 | 0.000 | -0.97 | -1.03 | -0.92 | 0.000 |
| 13 | DSM-IV Axis 5 | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 14 | Risk to Self Q1 | 27 | 10 | 37 | 0.73 | 0.60 | 0.89 | 0.002 | -0.27 | -0.41 | -0.13 | 0.000 |
| 15 | Risk to Self Q2 | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 16 | Risk to Self Q3 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 17 | Risk to Self Q4 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 18 | Risk to Others Q1 | 28 | 9 | 37 | 0.76 | 0.63 | 0.91 | 0.003 | -0.24 | -0.38 | -0.10 | 0.001 |
| 19 | Risk to Others Q2 | 35 | 2 | 37 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.13 | 0.02 | 0.146 |
| 20 | Risk to Others Q3 | 33 | 4 | 37 | 0.89 | 0.80 | 1.00 | 0.046 | -0.11 | -0.21 | -0.01 | 0.034 |
| 21 | Risk to Others Q4 | 32 | 5 | 37 | 0.86 | 0.76 | 0.98 | 0.025 | -0.14 | -0.25 | -0.02 | 0.016 |
| 22 | Risk to Others Q5 | 33 | 4 | 37 | 0.89 | 0.80 | 1.00 | 0.046 | -0.11 | -0.21 | -0.01 | 0.034 |
| 23 | Risk to Others Q6 | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 24 | Admit-Discharge-Follow-up | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 25 | Investigations | 25 | 12 | 37 | 0.68 | 0.54 | 0.84 | 0.001 | -0.32 | -0.48 | -0.17 | 0.000 |
| 26 | Psychological Input | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 27 | Community Support | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 28 | Drug Type | 64 | 11 | 75 | 0.85 | 0.78 | 0.94 | 0.001 | -0.15 | -0.23 | -0.07 | 0.000 |
| 29 | Drug Action | 58 | 17 | 75 | 0.77 | 0.68 | 0.87 | 0.000 | -0.23 | -0.32 | -0.13 | 0.000 |
| 30 | Drug Indication | 49 | 26 | 75 | 0.65 | 0.55 | 0.77 | 0.000 | -0.35 | -0.45 | -0.24 | 0.000 |
| 31 | DSM-IV Axis 1 (1) | 49 | 5 | 54 | 0.91 | 0.83 | 0.99 | 0.025 | -0.09 | -0.17 | -0.02 | 0.019 |
| 32 | DSM-IV Axis 2 (2) | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 33 | DSM-IV Axis 3 (3) | 36 | 2 | 38 | 0.95 | 0.88 | 1.02 | 0.157 | -0.05 | -0.12 | 0.02 | 0.146 |
| 34 | DSM-IV Axis 4 (4:12) | 276 | 57 | 333 | 0.83 | 0.79 | 0.87 | 0.000 | -0.17 | -0.21 | -0.13 | 0.000 |
| 35 | DSM-IV Axis 5 (13) | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 36 | Risk to Self (14:17) | 112 | 36 | 148 | 0.76 | 0.69 | 0.83 | 0.000 | -0.24 | -0.31 | -0.17 | 0.000 |
| 37 | Risk to Others (18:23) | 190 | 32 | 222 | 0.86 | 0.81 | 0.90 | 0.000 | -0.14 | -0.19 | -0.10 | 0.000 |
| 38 | Admit-Discharge-Follow-up (24) | 34 | 3 | 37 | 0.92 | 0.84 | 1.01 | 0.083 | -0.08 | -0.17 | 0.01 | 0.071 |
| 39 | Investigations (25) | 25 | 12 | 37 | 0.68 | 0.54 | 0.84 | 0.001 | -0.32 | -0.48 | -0.17 | 0.000 |
| 40 | Psychological Input (26) | 26 | 11 | 37 | 0.70 | 0.57 | 0.87 | 0.001 | -0.30 | -0.44 | -0.15 | 0.000 |
| 41 | Community Support (27) | 29 | 8 | 37 | 0.78 | 0.66 | 0.93 | 0.005 | -0.22 | -0.35 | -0.08 | 0.001 |
| 42 | Drug Type (28) | 64 | 11 | 75 | 0.85 | 0.78 | 0.94 | 0.001 | -0.15 | -0.23 | -0.07 | 0.000 |
| 43 | Drug Action (29) | 58 | 17 | 75 | 0.77 | 0.68 | 0.87 | 0.000 | -0.23 | -0.32 | -0.13 | 0.000 |
| 44 | Drug Indication (30) | 49 | 26 | 75 | 0.65 | 0.55 | 0.77 | 0.000 | -0.35 | -0.45 | -0.24 | 0.000 |
| 45 | DSM Diagnosis (1:13) | 421 | 78 | 499 | 0.84 | 0.81 | 0.88 | 0.000 | -0.16 | -0.19 | -0.12 | 0.000 |
| 46 | Risks (14:23) | 302 | 68 | 370 | 0.82 | 0.78 | 0.86 | 0.000 | -0.18 | -0.22 | -0.14 | 0.000 |
| 47 | Non-Drug Intervention (24:27) | 114 | 34 | 148 | 0.77 | 0.71 | 0.84 | 0.000 | -0.23 | -0.30 | -0.16 | 0.000 |
| 48 | Drug Intervention (28:30) | 171 | 54 | 225 | 0.76 | 0.71 | 0.82 | 0.000 | -0.24 | -0.30 | -0.18 | 0.000 |
A: Accurate outcome, I: Inaccurate Outcome, AR: Accuracy Ratio (Risk Ratio), LCI: Lower 95% Confidence Interval, UCI: Upper 95% Confidence Interval, RD: Risk Difference when the sample statistics compared with Accuracy (Risk) of 1 for the face-to-face interview. All approximated p values are more than zero.
Numbers in brackets represent index number of primary attributes serialised in the previous rows.
Drug Types- Atypical Antipsychotic, Mood Stabilizer, Tricyclic Antidepressant, Newer Antidepressant, Other Antidepressant, Benzodiazepine Group, Non-Benzodiazepine Anxolytic, Anti-Parkinsonian, and 'No Medication'.
Drug related actions were grouped into 'New Prescription', 'Continuation of previously prescribed medication with no change', and 'Adjustment of previously prescribed medication'.
Drug Indications were categorised for Positive Psychotic Symptoms, Manic symptoms, Bipolar Disorder, Depression, Anxiety and Associated Symptoms, Drugs for Side Effects (e.g. Anti-parkinsonian), Hypnotics, and Use of Drugs' sedative effect for anxiety control and sleep.
Cohen's Kappa results of intermethod and interviewers assessments
| 1 | DSM-IV Axis 1 | 54 | 26 | 0.28 | 1.00 | 0.33 | 1.00 | ||
| 2 | DSM-IV Axis 2 | 37 | 2 | 0.62 | -0.04 | 0.87 | 0.21 | 0.87 | |
| 3 | DSM-IV Axis 3 | 38 | 2 | 0.49 | 0.93 | 0.49 | 0.93 | ||
| 4 | DSM-IV Axis 4 Q1 | 37 | 2 | 0.25 | 0.82 | 0.22 | 0.83 | ||
| 5 | DSM-IV Axis 4 Q2 | 37 | 2 | 0.17 | -0.11 | 0.72 | 0.18 | -0.09 | 0.68 |
| 6 | DSM-IV Axis 4 Q3 | 37 | 2 | 0.66 | 0.91 | 0.66 | 0.91 | ||
| 7 | DSM-IV Axis 4 Q4 | 37 | 2 | 0.65 | 0.94 | 0.65 | 0.94 | ||
| 8 | DSM-IV Axis 4 Q5 | 37 | 2 | NA | NA | NA | NA | ||
| 9 | DSM-IV Axis 4 Q6 | 37 | 2 | 0.18 | 0.84 | 0.13 | 0.84 | ||
| 10 | DSM-IV Axis 4 Q8 | 37 | 2 | 0.36 | -0.07 | 0.79 | 0.37 | -0.08 | 0.54 |
| 11 | DSM-IV Axis 5 | 37 | 5 | 0.81 | 0.94 | 0.81 | 0.94 | ||
| 12 | Risk to self Q1 | 37 | 3 | 0.39 | 0.86 | 0.39 | 0.86 | ||
| 13 | Risk to self Q2 | 37 | 3 | 0.34 | 0.86 | 0.37 | 0.86 | ||
| 14 | Risk to self Q3 | 37 | 3 | 0.55 | -0.11 | 0.73 | 0.22 | 0.80 | |
| 15 | Risk to self Q4 | 37 | 3 | 0.45 | -0.11 | 0.68 | 0.12 | 0.79 | |
| 16 | Risk to others Q1 | 37 | 3 | 0.27 | 0.86 | 0.27 | 0.86 | ||
| 17 | Risk to others Q2 | 37 | 3 | 0.30 | 1.00 | 0.37 | 1.00 | ||
| 18 | Risk to others Q3 | 37 | 2 | -0.04 | -0.10 | -0.03 | -0.04 | -0.10 | -0.03 |
| 19 | Risk to others Q4 | 37 | 3 | 0.55 | -0.11 | 0.78 | 0.55 | -0.06 | 0.78 |
| 20 | Risk to others Q5 | 37 | 2 | 0.44 | -0.07 | 0.84 | 0.44 | -0.06 | 0.84 |
| 21 | Risk to others Q6 | 37 | 3 | 0.41 | -0.13 | 0.66 | 0.41 | -0.12 | 0.66 |
| 22 | Admit-Discharge-Follow up | 37 | 3 | 0.37 | 0.93 | 0.37 | 0.93 | ||
| 23 | Investigations | 37 | 2 | 0.29 | -0.03 | 0.59 | 0.30 | -0.02 | 0.59 |
| 24 | Psychological Input | 37 | 2 | 0.16 | -0.17 | 0.53 | 0.18 | -0.12 | 0.54 |
| 25 | Community Support | 37 | 2 | 0.22 | 0.78 | 0.25 | 0.78 | ||
| 26 | Drug Type | 75 | 9 | 0.61 | 0.90 | 0.52 | 0.90 | ||
| 27 | Drug Action | 75 | 5 | 0.52 | 0.79 | 0.52 | 0.79 | ||
| 28 | Drug Indication | 75 | 11 | 0.35 | 0.74 | 0.35 | 0.76 | ||
| 29 | DSM-IV Axis 1 (1) | 54 | 26 | 0.28 | 1.00 | 0.33 | 1.00 | ||
| 30 | DSM-IV Axis 2 (2) | 37 | 2 | 0.62 | -0.04 | 0.87 | 0.21 | 0.87 | |
| 31 | DSM-IV Axis 3 (3) | 38 | 2 | 0.49 | 0.93 | 0.49 | 0.93 | ||
| 32 | DSM-IV Axis 4 (4:10) | 259 | 14 | 0.52 | 0.78 | 0.52 | 0.78 | ||
| 33 | DSM-IV Axis 5 (11) | 37 | 5 | 0.81 | 0.94 | 0.81 | 0.94 | ||
| 34 | Risk to self (12:15) | 148 | 12 | 0.48 | 0.75 | 0.48 | 0.75 | ||
| 35 | Risk to Others (16:21) | 222 | 16 | 0.05 | -0.01 | 0.11 | 0.05 | -0.01 | 0.11 |
| 36 | Admit-Discharge-Follow up (22) | 37 | 3 | 0.37 | 0.93 | 0.37 | 0.93 | ||
| 37 | Investigations (23) | 37 | 2 | 0.29 | -0.03 | 0.59 | 0.30 | -0.02 | 0.59 |
| 38 | Psychological Input (24) | 37 | 2 | 0.16 | -0.17 | 0.53 | 0.18 | -0.12 | 0.54 |
| 39 | Community Support (25) | 37 | 2 | 0.22 | 0.78 | 0.25 | 0.78 | ||
| 40 | Drug Type (26) | 75 | 9 | 0.61 | 0.90 | 0.52 | 0.90 | ||
| 41 | Drug Action (27) | 75 | 5 | 0.52 | 0.79 | 0.52 | 0.79 | ||
| 42 | Drug Indication (28) | 75 | 11 | 0.35 | 0.74 | 0.35 | 0.76 | ||
| 43 | DSM-IV (1:11) | 425 | 49 | 0.81 | 0.90 | 0.81 | 0.90 | ||
| 44 | Risks (12:21) | 370 | 28 | 0.08 | 0.19 | 0.09 | 0.19 | ||
| 45 | Non-Drug Intervention (22:25) | 148 | 9 | 0.35 | 0.64 | 0.35 | 0.64 | ||
| 46 | Drug Intervention (26:28) | 225 | 25 | 0.66 | 0.79 | 0.66 | 0.79 | ||
| 47 | Overall Result (1:28) | 1168 | 111 | 0.57 | 0.63 | 0.57 | 0.63 | ||
The column 'Size' constitutes the number of total sample points used for assessments.
The column 'Group' stands for the number of total categories of results e.g. all diagnoses with Paranoid Schizophrenia will make one group.
CK: Cohen's Kappa values derived from 'n by n' table made from the Groups. The significant values (Lower CI more than 0) are printed in bold. The summary CK results in the rows from 29 to 47 are based on "Inverse Variance method" using CKs and variances from previous rows displayed in the brackets for the respective assessments.
95% Lower & Upper Confidence Intervals (LCI and UCI) from the rows 1 to 28 are derived from non-parametric Bias Corrected Accelerated (BCa) variance from 50,000 bootstrap samples with replacement. The summary LCIs and UCIs in the rows from 29 to 47 are based on "Inverse Variance method" using CKs and original variances from previous rows are displayed in the brackets for the respective assessments.
Weighted Kappa using "square error weights" were computed for ordinal observations where applicable.
The definitions for Drug Type, Drug Action and Drug Indication are same as in the Table 1.
| • Dangerous or threatening actions | N | L | M | H | V |
| • Verbal/non-verbal risks | N | L | M | H | V |
| • Deliberate self harm | N | L | M | H | V |
| • Aggression | N | L | M | H | V |
| • Arousal, anger, hostility, irritability, suspiciousness, fear | N | L | M | H | V |
| • Low mood or elevated mood | N | L | M | H | V |
| • Fantasies of deliberate self harm or harm to others | N | L | M | H | V |
| • Persecutory thoughts, delusions | N | L | M | H | V |
| • External control | N | L | M | H | V |
| • Confusion | N | L | M | H | V |
| • Preoccupation, obsession, jealousy | N | L | M | H | V |
| • Control over-ride | N | L | M | H | V |
| • Cultural beliefs | N | L | M | H | V |
| • Command hallucinations | N | L | M | H | V |
| • Misidentification | N | L | M | H | V |
| • Matakite | N | L | M | H | V |
| • Substance use, intoxication or withdrawal | N | L | M | H | V |
| • Relationships | N | L | M | H | V |
| • Presence or absence of support | N | L | M | H | V |
| • Absence of treatment, non compliance | N | L | M | H | V |
| • Persecution or threats from others | N | L | M | H | V |
| • Arrest or criminal charges | N | L | M | H | V |
| • Loss including death of a peer | N | L | M | H | V |
| • Cultural transgression | N | L | M | H | V |
| • Financial stress | N | L | M | H | V |
| • To weapons, pills, victims | N | L | M | H | V |
| • Referral from Prison, Police, Secure Unit | N | L | M | H | V |
| • Co-operation | N | L | M | H | V |
| • Refusal to co-operate or fear of compulsory treatment | N | L | M | H | V |
| • Patterns of illness – Chronic active, Neurological disorder, H/O Head injury | N | L | M | H | V |
| • Psychiatric history – Serious mental illness, Multiple diagnoses, Treatment under MHA | N | L | M | H | V |
| • History of incidents (and context) – Repeated antisocial behavior | N | L | M | H | V |
| • Treatment and outcomes – Compliance and response of treatment given in past | N | L | M | H | V |
| • Features of past crises – Pathological intoxication, Episodic dyscontrol, Cruelty to animals, Blackouts | N | L | M | H | V |
| • Personal history – Criminal charges, Previous offenses, Forensic involvement | N | L | M | H | V |
| • Usual coping style – Loner, Displaced rage reaction, self mutilism, Impulsivity, denial, Blaming others | N | L | M | H | V |
| • Demographics – Single, Male, Poor, Low educational and vocational success | N | L | M | H | V |
| • Culture – Tolerance to antisocial behavior, Reluctance to disclose, Shame & Guilt | N | L | M | H | V |
| • Dynamics – H/O Violence, Contact of violent gangs, Intrafamilial violence | N | L | M | H | V |
| 1. Safety (including suicidal acts, deliberate self harm) | N | L | M | H | V |
| 2. Health (incl. drug & alcohol abuse, physical & psychological harm) | N | L | M | H | V |
| 3. Self neglect and vulnerability (incl. exploitation, sexual abuse, violence from others) | N | L | M | H | V |
| 4. Quality of life (including dignity, social and financial status) | N | L | M | H | V |
| 1. Violence (including emotional, sexual and physical violence) | |||||
| 2. Intimidation/threats | N | L | M | H | V |
| 3. Neglect/abuse of Dependants | N | L | M | H | V |
| 4. Stalking/harassment | N | L | M | H | V |
| 5. Reckless behavior (including driving)Property damage (including arson) | N | L | M | H | V |
| 6. Public nuisance | N | L | M | H | V |
LIST OF PSYCHIATRIC INTERVENTION (LIPI)
| Admission |
| Discharge |
| Followup |
| Haematological |
| Biochemical |
| Serum Level of Medication |
| ECG tests |
| EEG Examination |
| CT/NMRI/PET/Isotope/Ultrasound |
| IQ Assessment |
| Other biological test |
| Other Psychological Tests |
| Investigation |
| Simple Explanations |
| Support & Advice |
| Self Help by Book |
| Self Help Group |
| Assertiveness Training |
| Anger Control |
| Domestic Skills Training |
| Budget Handling Training |
| Social Skill Training |
| Counselling |
| Marital Therapy |
| Divers ional Therapy |
| Relaxation Training |
| Paper bag Ventilation |
| Systemic Desensitisation |
| Biofeedback |
| Cognitive Behaviour Therapy |
| Psychotherapy |
| Family Therapy |
| Other |
| CPN visit to support patient |
| CPN visit to support family |
| Activity Therapy (Gym, sports etc) |
| Handling Bills and Finances |
| Helping in making Applications to other agencies |
| Outreach |
| Home Help |
| Meals on Wheels |
| Art & Work therapy (Art, wood, gardening) |
| Day Hospital for socialisation |
LIPI-5: Information related to Drug Type, Action and Indication scored in different table